Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

A user experiencing hair loss since age 18 is considering switching from finasteride and minoxidil to dutasteride after poor results and lifestyle choices. They plan to improve their lifestyle and get blood work done to assess treatment effectiveness.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Topical and oral spironolactone show potential in improving hair growth when combined with topical Minoxidil.

A user is experiencing side effects like less hard erections and sensitive nipples while on finasteride, with bloodwork showing high prolactin levels. They are seeking suggestions to address the prolactin issue.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.

The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.

The conversation discusses being overwhelmed by the variety of hair loss treatments, including finasteride, minoxidil, ketoconazole shampoo, caffeine shampoo, and other supplements like biotin and saw palmetto. The user expresses uncertainty about which treatments to use.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

The impact of creatine on DHT levels, and whether it could cause accelerated male pattern baldness (MPB). The user taking a 5 alpha reductase inhibitor found that their DHT levels actually reduced despite taking creatine for nine weeks. Replies suggested looking into testosterone levels as well and debating the safety of creatine use in relation to MPB.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The conversation is about a finding that finasteride does not significantly increase the risk of sexual dysfunction, with users sharing mixed personal experiences regarding side effects.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Matt-3422 shared his hair loss treatment journey, starting with great results from Minoxidil and oral Finasteride, then switching to RU58841 and topical Finasteride due to worsening hair loss. He's experiencing scalp irritation and is unsure if he should continue with his current regimen, while others suggest scalp care and alternative treatments.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The user is considering resuming finasteride after a 6-month break and is debating the necessity of extensive blood work, including hormone and health markers, to establish a baseline. They are unsure if the tests are necessary since they experienced no side effects previously.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.

The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.